A cell and gene therapy company scaling development programs and preparing to onboard new vendors for plasmids, viral vectors, raw materials, and .

A biotechnology company advancing multiple ATMP candidates toward regulatory milestones with limited internal CMC bandwidth.

A next generation CAR-T therapy company transitioning from an academic manufacturing process to a commercial capable CDMO platform.

An early stage gene therapy company developing multiple AAV programs with limited internal quality infrastructure.

A clinical stage cell therapy company preparing to expand its manufacturing capacity to support Phase Two and Phase Three material.